News
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
18h
MedPage Today on MSNZepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
The U.S. Food and Drug Administration (FDA) has issued a warning to patients and healthcare professionals regarding the use ...
16h
Newser on MSNMounjaro Beats Ozempic in Head-to-Head StudyMounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results